Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518624 | 0.88 | EPHX2 (0.76) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL7779037 | 0.85 | EPHX2 (0.61) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL669442 | 0.84 | EPHX2 (0.70) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL8401862 | 0.84 | DHODH (0.66) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL10040308 | 0.84 | DHODH (0.66) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL11428736 | 0.82 | EPHX2 (0.68) | EPHX2DHODHKIF11TGM2NPC1 | |
| SCHEMBL21138717 | 0.81 | EPHX2 (0.61) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL8241427 | 0.81 | DHODH (0.62) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| SCHEMBL12706753 | 0.81 | DHODH (0.62) | EPHX2DHODHALDH1A1TRPV1KIF11 | |
| Nitrogen SCHEMBL28799837 | 0.81 | SMN1; SMN2 (0.66) | EPHX2DHODHALDH1A1TRPV1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | EPHX2 2126/4885DHODH 930/4885ALDH1A1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.